Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **antigen-presenting cell and T-cell activation pathway** refers to the series of coordinated cellular and molecular interactions that trigger adaptive immune responses. Antigen-presenting cells—chiefly dendritic cells, macrophages, and B cells—capture, process, and present antigenic peptides to T cells via major histocompatibility complex (MHC) molecules[1][8]. Activation of T cells requires two principal signals: (1) the T-cell receptor (TCR) recognizes the antigen peptide-MHC complex, and (2) co-stimulatory molecules (such as CD80 or CD86 on the APC interacting with CD28 on the T cell) deliver a required second signal for full T-cell activation[1][6][3]. Without both signals, T cells become anergic or tolerant[3]. Signaling cascades downstream of TCR and co-stimulatory engagement activate kinases, phosphatases, and transcription factors, leading to T-cell proliferation, cytokine production, and effector function[5][7]. This pathway is central to effective immunity against infection, tumor surveillance, and is targeted in immunotherapy and autoimmune disease treatments[6][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Antigen-presenting cell and T-cell activation pathway.